| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $80,206,948 | 33 | 100 |
| ABERNETHY MATT | Chief Financial Officer | 0 | $0 | 1 | $363,285 | $-363,285 |
| Boyer David W. | Chief Corp. Affairs Officer | 0 | $0 | 2 | $739,074 | $-739,074 |
| BENEVICH ERIC | Chief Commercial Officer | 0 | $0 | 2 | $1.24M | $-1.24M |
| Norwalk Leslie V | director | 0 | $0 | 5 | $1.97M | $-1.97M |
| LYONS GARY A | director | 0 | $0 | 1 | $2.29M | $-2.29M |
| POPS RICHARD F | director | 0 | $0 | 1 | $2.36M | $-2.36M |
| RASTETTER WILLIAM H | director | 0 | $0 | 1 | $2.73M | $-2.73M |
| Onyia Jude | Chief Scientific Officer | 0 | $0 | 2 | $3.47M | $-3.47M |
| Delaet Ingrid | Chief Regulatory Officer | 0 | $0 | 5 | $3.75M | $-3.75M |
| SHERWIN STEPHEN A | director | 0 | $0 | 1 | $4.13M | $-4.13M |
| Lippoldt Darin | Chief Legal Officer | 0 | $0 | 4 | $4.2M | $-4.2M |
| MORROW GEORGE J | director | 0 | $0 | 4 | $4.49M | $-4.49M |
| Gano Kyle | Chief Executive Officer | 0 | $0 | 2 | $4.87M | $-4.87M |
| Cooke Julie | Chief Human Resources Officer | 0 | $0 | 1 | $5.77M | $-5.77M |
| GORMAN KEVIN CHARLES | director | 0 | $0 | 1 | $37.82M | $-37.82M |
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive …
Over the last 12 months, insiders at Neurocrine Biosciences, Inc. have bought $0 and sold $80.21M worth of Neurocrine Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Neurocrine Biosciences, Inc. have bought $0 and sold $64.06M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 59,000 shares for transaction amount of $351,345 was made by BVF PARTNERS L P/IL (10 percent owner) on 2011‑10‑12.
| 2026-11-03 | Sale | MORROW GEORGE J | director | 7,200 0.0071% | $166.37 | $1.2M | -0.91% | |
| 2026-11-02 | Sale | MORROW GEORGE J | director | 7,500 0.0074% | $145.79 | $1.09M | +13.07% | |
| 2026-10-30 | Sale | MORROW GEORGE J | director | 300 0.0003% | $149.00 | $44,700 | ||
| 2026-09-14 | Sale | ABERNETHY MATT | Chief Financial Officer | 2,311 0.0023% | $157.20 | $363,285 | -9.32% | |
| 2026-09-14 | Sale | Boyer David W. | Chief Corp. Affairs Officer | 826 0.0008% | $157.45 | $130,051 | -9.32% | |
| 2026-09-09 | Sale | BENEVICH ERIC | Chief Commercial Officer | 2,154 0.0021% | $154.61 | $333,030 | -7.71% | |
| 2026-07-28 | Sale | Norwalk Leslie V | director | 1,250 0.0012% | $182.01 | $227,508 | -17.51% | |
| 2026-07-10 | Sale | Delaet Ingrid | Chief Regulatory Officer | 4,367 0.0044% | $181.02 | $790,514 | -13.40% | |
| 2026-07-09 | Sale | Lippoldt Darin | Chief Legal Officer | 10,000 0.0099% | $179.60 | $1.8M | -14.87% | |
| 2026-07-09 | Sale | Delaet Ingrid | Chief Regulatory Officer | 8,433 0.0084% | $178.72 | $1.51M | -14.87% | |
| 2026-07-08 | Sale | Delaet Ingrid | Chief Regulatory Officer | 2,737 0.0027% | $178.54 | $488,672 | -13.58% | |
| 2026-07-07 | Sale | Delaet Ingrid | Chief Regulatory Officer | 3,401 0.0034% | $178.57 | $607,305 | -13.21% | |
| 2026-06-29 | Sale | Lippoldt Darin | Chief Legal Officer | 9,800 0.0098% | $170.16 | $1.67M | -9.12% | |
| 2026-06-26 | Sale | Lippoldt Darin | Chief Legal Officer | 200 0.0002% | $169.56 | $33,913 | -8.14% | |
| 2026-06-05 | Sale | SHERWIN STEPHEN A | director | 25,000 0.0251% | $165.32 | $4.13M | -4.53% | |
| 2026-06-04 | Sale | Norwalk Leslie V | director | 1,250 0.0012% | $168.06 | $210,072 | -6.49% | |
| 2026-06-02 | Sale | Cooke Julie | Chief Human Resources Officer | 36,937 0.0371% | $156.22 | $5.77M | +1.12% | |
| 2026-06-01 | Sale | Onyia Jude | Chief Scientific Officer | 11,000 0.0109% | $160.25 | $1.76M | -2.78% | |
| 2026-05-29 | Sale | Delaet Ingrid | Chief Regulatory Officer | 2,261 0.0022% | $156.71 | $354,321 | -1.09% | |
| 2026-05-27 | Sale | Onyia Jude | Chief Scientific Officer | 11,000 0.0109% | $155.53 | $1.71M | +0.47% |
| BVF PARTNERS L P/IL | 10 percent owner | 3527700 3.4705% | $581.54M | 36 | 10 | <0.0001% |
| MITCHELL W THOMAS | director | 1000 0.001% | $164,850.00 | 2 | 7 | +29.05% |
| Increased Positions | 427 | +67.67% | 11M | +11.22% |
| Decreased Positions | 268 | -42.47% | 9M | -8.89% |
| New Positions | 140 | New | 2M | New |
| Sold Out Positions | 42 | Sold Out | 1M | Sold Out |
| Total Postitions | 790 | +25.2% | 100M | +2.33% |
| Blackrock, Inc. | $1.79M | 12.71% | 12.71M | -248,535 | -1.92% | 2025-09-30 |
| Vanguard Group Inc | $1.36M | 9.71% | 9.71M | -100,507 | -1.02% | 2025-09-30 |
| Dodge & Cox | $781,260.00 | 5.56% | 5.56M | -10,196 | -0.18% | 2025-09-30 |
| Jpmorgan Chase & Co | $665,059.00 | 4.73% | 4.73M | +468,405 | +10.99% | 2025-09-30 |
| State Street Corp | $611,115.00 | 4.35% | 4.35M | -121,787 | -2.73% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $403,062.00 | 2.87% | 2.87M | -219,726 | -7.12% | 2025-09-30 |
| Aqr Capital Management Llc | $389,975.00 | 2.77% | 2.77M | +1M | +83.68% | 2025-09-30 |
| Renaissance Technologies Llc | $340,013.00 | 2.42% | 2.42M | +51,900 | +2.19% | 2025-09-30 |
| Geode Capital Management, Llc | $284,690.00 | 2.03% | 2.02M | +65,560 | +3.35% | 2025-09-30 |
| Morgan Stanley | $256,867.00 | 1.83% | 1.83M | +7,192 | +0.4% | 2025-09-30 |